With no cure in sight, any new approval ushers in hope, including with an agent like Leqembi that slowed progression of the disease an average of 27% in research.
https://ift.tt/BXF3mPQ
from WebMD Health https://ift.tt/H7y5mu2
by
With no cure in sight, any new approval ushers in hope, including with an agent like Leqembi that slowed progression of the disease an average of 27% in research.
Comments
Post a Comment